<DOC>
	<DOCNO>NCT00612430</DOCNO>
	<brief_summary>Primary Objective estimate 6-month progression free survival probability patient recurrent malignant glioma treat Etoposide + Bevacizumab . Secondary Objectives To evaluate safety &amp; tolerability Etoposide + Bevacizumab among patient recurrent malignant glioma ( RMG ) . To evaluate radiographic response , progression free survival &amp; overall survival patient recurrent malignant glioma treat Etoposide + Bevacizumab .</brief_summary>
	<brief_title>Ph II Bevacizumab + Etoposide Pts w Recurrent MG</brief_title>
	<detailed_description>Exploratory , single-arm , ph II study design assess anti-tumor activity combinatorial regimen consist Etoposide + Bevacizumab among patient RMG . Primary endpoint study probability progression-free survival 6 month . Important secondary objective ass safety Etoposide &amp; Bevacizumab patient recurrent malignant glioma . If study demonstrate combinatorial regimen Etoposide + Bevacizumab associate encouraging anti-tumor activity among patient RMG , assessment regimen additional phase II &amp; possibly phase III study , consider .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Pts confirm diagnosis recurrent/progressive WHO gr III &amp; IV MG Age &gt; 18 r Interval &gt; 4 wks since prior surgery Interval &gt; 4 wks since prior XRT/chemo , unless unequivocal evidence progressive disease &amp; pt recover anticipated toxicity recent therapy ; Karnofsky performance status score &gt; 60 Hematocrit &gt; 29 percent , ANC &gt; 1,500 cells/microliter , platelet &gt; 100,000 cells/microliter Serum creatinine &lt; 1.5 mg/dl , BUN &lt; 25 mg/dl , serum SGOT &amp; bilirubin &lt; 1.5 x ULN For pt corticosteroid , astable dose 1wk prior entry Signed informed consent approve IRB prior pt entry If sexually active , pt must agree take contraceptive measure duration treatment . Prior therapy w either bevacizumab/etoposide &gt; 3 prior recurrence Pregnancy/breast feed Comedication w immunosuppressive agent corticosteroid include limited cyclosporine , tacrolimus , sirolimus , mycophenolate mofetil Evidence CNS hemorrhage baseline MRI CT scan Pts require therapeutic anticoagulation Uncontrolled intercurrent illness include , limited , ongoing active infection require IV antibiotic &amp; psychiatric illness/social situation would limit compliance w study requirement , disorder associate w significant immunocompromised state Pts w another primary malignancy require treatment &lt; past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>GBM</keyword>
	<keyword>MG</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VP-16</keyword>
	<keyword>Etopophos</keyword>
	<keyword>Toposar</keyword>
	<keyword>VePesid</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Recurrent GBM</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Malignant glioma</keyword>
</DOC>